IDH1 and central nervous system cancer: In this large-scale Chinese cohort, we first confirmed a strong link between tumor location and molecular subtype: Frontal gliomas had IDH1/2 mutations in 63.5% of cases, while temporal (80.3%) and thalamic/basal ganglia gliomas (90.4%) were predominantly IDH1/2-wild-type.